Journal of Vascular Medicine & Surgery

ISSN: 2329-6925

Journal of Vascular Medicine & Surgery
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business

When are Endografts the Best Treatment for Aortic Infection? And When are they Not?

Francesco Setacci1,2 and Massimo Fioranelli3,4*
1Department of Surgery, Sapienza University of Rome, Rome, Italy
2Department of Medicine, Surgery and Neuroscience, University of Siena, Italy
3University B.I.S. group of institutions, Punjab Technical University, Punjab, India
4Centre for Studies in Science of Life, Guglielmo Marconi University, Rome, Italy
Corresponding Author : Massimo Fioranelli
Centre for Studies in Science of Life
Guglielmo Marconi University, Rome, Italy
Tel: +3906802206007
Received November 14, 2014; Accepted November 14, 2014; Published November 16, 2014
Citation: Setacci F, Fioranelli M (2014) When are Endografts the Best Treatment for Aortic Infection? And When are they Not?. J Vasc Med Surg 2:e115. doi: 10.4172/2329-6925.1000e115
Copyright: © 2014 Setacci F et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at
DownloadPubmed DownloadScholar Google
Visit for more related articles at Journal of Vascular Medicine & Surgery
Aortic infection; Endografts; Mycotic aneurysm
Aortic infection is an uncommon but severe condition, regardless of whether it occurs in the setting of bacteremia (mycotic aneurysm) or as a complication of atherosclerotic aneurysm or pseudoaneurysm after open aortic surgery. Frequently, aortic infection is associated with a primary or secondary fistula into the esophagus or upper airway in the thorax or the gastrointestinal system in the abdomen. In these cases the onset of symptoms could be directly an acute bleeding requiring emergency treatment. Sometimes the patients could develop sepsis. Conventional open surgical repair (OR) is still today considered the best treatment but is associated with considerable morbidity and mortality. In this setting, endovascular aneurysm repair (EVAR) appears to offer promise when used for emergency and palliative treatment especially in high-risk patients. EVAR is even more appealing when OR is complicated by the presence of inflammation, scarring, bleeding, or hemodynamic instability. In the last decade, a number of case reports of successful initial treatment of aortic infections using EVAR have been reported, suggesting wider use of this approach. But when are endografts the best treatment for aortic infection? And when are they not?
Endograft for Mycotic Aneurysm
Nowadays, mycotic aortic aneurysms represent 1% to 2% of all aortic aneurysms [1]. The “gold standard” of therapy involves surgical resection of the infected aorta, debridement of infected peri-aortic tissues, and reconstruction of aortic flow by either an in situ interposition of silver graft/homograft or extra-anatomic bypass followed by long-term antibiotic therapy [2]. Unfortunately, OR in patients in poor clinical condition, and with severe associated comorbidities, still results in high morbidity and mortality (up to 40%) [3]. During the last years EVAR has been proposed as alternative in the management of such aneurysms. The procedure offers technical advantages compared with OR, but concerns remain about endograft placement in an infected field. The first reported case of EVAR for mycotic aneurysms was by Semba et al. [4]. After this report, several authors have described similar endovascular approaches with remarkable results [5-12]. Nevertheless, whether EVAR or TEVAR can actually be considered as definitive treatment for mycotic aneurysms remains an open question.
Endograft for Aorto-bronchial Fistula
Aortobronchial Fistulas (ABFs) are defined as communications between the thoracic aorta and the adjacent tracheobronchial system [13], generating aortic infection and acute bleeding. ABFs can developed in different thoracic aorta pathologies, including atherosclerotic aneurysms, penetrating aortic ulcers, anastomotic pseudoaneurysms after open aortic surgery, mycotic aneurysms, and traumatic thoracic aorta injuries [14]. ABFs are highly fatal if not diagnosed and treated quickly. Although clinical presentation is typical: hemoptysis, either intermittent or massive, a definitive diagnosis is not easy because there is no diagnostic test that can clearly demonstrate the presence of the fistula. In fact, computed tomography imaging rarely shows the communication between the aorta and the esophagus. Suggestive indirect signs of the fistulous tract are present in many cases and include air bubbles into the aorta, periaortic fluid collection, esophageal wall thickening, and lung parenchymal changes. Despite advances OR techniques, open repair still has a high operative mortality ranging from 15% to 41% related to the thoracotomy [15], the need for cross-clamping of the descending thoracic aorta, and direct repair or arterial bypass of the aortic defect, with concomitant resection or reconstruction of involved bronchial segments. The first TEVAR for ABF was described by Chuter et al. [16]. With refinement of endovascular techniques, TEVAR now represents a valid alternative for ABFs, offering the advantage of fast control of bleeding and avoiding major trauma related with OR. Experience is still limited because of the rarity of this clinical condition. The available data are largely restricted to individual case reports or small series [17-19].
Several concerns still remain about the potential of ABFs recurrence, persistent endograft infection, and late endograft complications, such as migration, remodeling, or disconnection. Whether TEVAR is a definitive procedure for ABF or a temporizing treatment to obtain prompt bleeding control remains to be defined. Unfortunately, little is still known about the long-term durability of TEVAR for this condition.
Endograft for Aorto-enteric Fistulas
Aortoenteric fistula (AEF) is defined as abnormal communication between the aortic and the bowel lumen with high risk of aortic infection and acute bleeding. AEF is a serious condition requiring immediate surgical intervention. We can classify AEFs in primary and secondary. The first can take place either as a primary procedure involving the aorta and the gastrointestinal tract or, more frequently, secondary to previous aortic reconstructive surgery or endovascular repair. Primary AEFs are extremely rare, ranging from 0.02% to 0.07% in autopsy studies. However, during the past 3 decades, erosion of the bowel (usually the distal duodenum) by prosthetic vascular grafts has become a more common cause and secondary AEFs have been reported to have reached an incidence of up to 4% in patients after aortic reconstruction, usually for aortic aneurysm. Symptoms at onset include hemodynamic instability secondary to gastrointestinal haemorrhage with or without signs of sepsis. The objective included bleeding control, maintenance of adequate distal perfusion, and control of infection. OR might achieve all three goals, but is accompanied by high morbidity and mortality rates (biblio) [20,21].
The OR strategy for revascularization included the aortic replacement with the interposition of silver graft or homograft. The extra anatomical revascularization associated with infrarenal aortic stump suture is associated with high risk of post-operative aortic bleeding due to erosion of the aortic stump suture line and long-term patency of the extra-anatomical revascularization.
EVAR can be considering a valid therapeutic option especially in case of haemodynamic instability. In fact this strategy represents a bridge option allowing definitive repair at a later time, after optimization of the patients’ condition [22].
When are Endografts the Best Treatment for Aortic Infection? and when are they not?
According with the most recent reported series and with our experience the endovascular repair can be considered a valid alternative option compared with classical open surgery in case of aortic infection but in selected patients. In several cases it could be considered also as the best and definitive treatment. For example in high risk and old patients considered unfit for open repair even after the stabilization of clinical condition. In this kind of patients the only endovascular therapy associated with adequate antibiotic therapy could be enough and can decrease radically the mortality associated with the treatment of this cohort of patients.
EVAR represents also the best treatment in case of haemodynamic instability of the patients and offers the possibility to stabilize their clinical condition in order to get to the definitive treatment in better conditions.
In younger patients without significant comorbidities the best therapeutic option remain still today the classical open surgery who allows the definitive solution of the problem and the endovascular repair should be indicated as “bridge approach” only in case of haemodynamic instability. Finally a feasible emergency-treatment option for aorto-bronchial and aorto-esophageal is to stop the aortic bleeding with TEVAR, then to remedy the esophageal or bronchial defect the interposition of intercostal muscle flap could be useful.


Select your language of interest to view the total content in your interested language
Post your comment
Share This Article
Relevant Topics
Disc Abdominal Aortic Aneurysm
Disc Arteries
Disc Arteriosclerosis
Disc Blood Clot Symptoms
Disc Brain Aneurysm Symptoms
Disc Cardiac Arrest
Disc Cardiac Cachexia
Disc Cardiac Dysrhythmias
Disc Cardiopulmonary Resuscitation
Disc Cardiovascular Drugs
Disc Cardiovascular Drugs Market Analysis
Disc Cardiovascular Medicine
Disc Cardiovascular Pharmacotherapy
Disc Cardiovascular Physiology
Disc Cardiovascular Safety Pharmacology
Disc Cardiovascular Toxicology
Disc Carotid Artery
Disc Cineangiography
Disc Congestive Heart Failure
Disc Coronary Heart Disease
Disc Cyanotic Heart Disease
Disc Emerging Infectious Diseases
Disc Endocrine Surgery
Disc Epidemiology
Disc Femoral Artery
Disc Gastrointestinal drugs and market analysis
Disc Gynecologic Surgery
Disc Heart Disease
Disc Hip surgery
Disc Hydrocele surgery
Disc Hypotension
Disc Ischemic Heart Disease
Disc Laparoscopic Surgery
Disc Laparotomy surgery
Disc Laser Surgery
Disc Liver Resection Surgery
Disc Liver surgery
Disc Liver transplant surgery
Disc Minimally invasive surgery
Disc Myocardial Infarction
Disc Neck surgery
Disc Neglected Tropical Diseases
Disc Neonatal Surgery
Disc Noncommunicable Diseases
Disc Oculoplastic surgery
Disc Oncologic Surgery
Disc Outpatient surgery
Disc Peripheral Vascular Disease
Disc Plantal fasciitis surgery
Disc Rheumatic Heart Disease
Disc Robotic Surgery
Disc Sciaticia surgery
Disc Stent
Disc Surgical oncology
Disc Thoracic surgery
Disc Toe surgery
Disc Transplant Surgery
Disc Trauma Surgery
Disc Tropical Biomedicine
Disc Tropical Diseases
Disc Tropical Fish Diseases
Disc Tropical Fish Medicine
Disc Tropical Health Nutrition
Disc Tropical Medicine
Disc Tropical Medicine Case Reports
Disc Tropical Medicine Research
Disc Tropical Medicine and Health
Disc Tropical Medicine and Hygiene
Disc Tropical Medicine and Infectious Diseases
Disc Tropical Medicine and Parasitology
Disc Tropical Veterinary Medicine
Disc Varicose surgery
Disc Vascular
Disc Vascular Dementia
Disc Vector Borne Diseases
Disc Vitreoretinal Surgery
Recommended Journals
Disc Cardiovascular Research Journal
Disc Endovascular Surgery Journal
Disc Cardiology Journal
Disc Pharmacology Journal
Disc Surgery Journal
Disc Tropical Medicine Journal
Disc Current Research in Surgery Journal
Disc Cardiovascular Pharmacology Journal
  View More»
Recommended Conferences
Disc World Congress On Vascular Diseases, Medicine & Surgeons Summit
October 24-25, 2016 Chicago, Illinois, USA
Disc Cardiology Congress
Oct 17-19, 2016 Rome, Italy
Disc Nursing and Healthcare
Dec 05-07, 2016, Dallas, USA
View More»
Article Tools
Disc Export citation
Disc Share/Blog this article
Article usage
  Total views: 11308
  [From(publication date):
December-2014 - Oct 22, 2016]
  Breakdown by view type
  HTML page views : 7562
  PDF downloads :3746

Post your comment

captcha    Reload  Can't read the image? click here to refresh

OMICS International Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
OMICS International Conferences 2016-17
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

1-702-714-7001Extn: 9037

Business & Management Journals


1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

1-702-714-7001 Extn: 9042

© 2008-2016 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version